Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Monoclonal antibodies in high-grade gliomas].

Vestnik Rossiiskoi akademii meditsinskikh nauk - 1 Jan 2014

Chekhonin I V, Leopold A V, Gurina O I, Semenova A V

Abstract excerpt

The review is devoted to a relatively young direction in therapy of malignant gliomas, which is based on applying monoclonal antibodies against tumour-associated antigens. The current data on efficacy of main therapeutic agents in clinical practice or clinical trials concerning high-grade gliomas, especially glioblastoma multiforme, is summarized. Of particular interest is bevacizumab, a humanized monoclonal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Bevacizumab
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Central Nervous System Neoplasms

Share to Glioma

Share to Vascular Endothelial Growth Factor A

Share to Vascular Endothelial Growth Factor Receptor-1

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Identifiers

PMID: 25816654
DOI: 10.15690/vramn.v69i9-10.1142

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Monoclonal antibodies in high-grade gliomas].PMID 25816654Read ↗

Current data and strategy in glioblastoma multiforme.Semantic proximity Read ↗

Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.Semantic proximity Read ↗

[Antibody therapy in cancer].Semantic proximity Read ↗

Gene therapy in glioblastoma multiforme: Can it be a role changer?Semantic proximity Read ↗

Epidermal growth factor receptorSemantic proximity Read ↗

A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignanciesSemantic proximity Read ↗

Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome ResistanceSemantic proximity Read ↗

Development of a Recombinant Monospecific Anti-PLGF Bivalent Nanobody and Evaluation of it in Angiogenesis Modulation.Semantic proximity Read ↗

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.Semantic proximity Read ↗

Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targetingSemantic proximity Read ↗

Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastomaSemantic proximity Read ↗

[Targeted therapies with BRAF inhibitors for pediatric low- and high-grade gliomas with BRAFv600e mutation. Prof. Dr. Juan P. Garrahan Hospital experience].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.